Diuretic Downsides—But in Low Doses They Still Seem Among the Best Authenticated Antihypertensives
Tóm tắt
Diuretics in low doses have the greatest support among current available antihypertensives in that they have been shown to reduce total mortality, coronary mortality, stroke, and congestive heart failure in an important meta-analysis by Psaty. Recently, Messerli has linked long-term diuretic use to renal cell carcinoma in women. In some patients, diuretic use leads to increasing blood cholesterol and blood sugar levels. Impotence is a recognized side effect, with rates rising about twofold with low-dose chlorthalidone and fourfold with a higher dose. Certain population groups such as younger (<60 years) white males often do not respond to low-dose diuretic therapy with an adequate blood pressure fall. In females of a similar age group, Messerli calculates that prolonged diuretic therapy will prevent only one stroke and no coronary events nor any deaths for every renal cell carcinoma that is provoked. Despite these evident problems, the outcome data on hard endpoints in trials with initial low-dose diuretic therapy remain valid and convincing. Thus, it is argued, low- but not high-dose diuretics retain their primacy in the ranking of antihypertensive therapy.
Tài liệu tham khảo
JNC VI. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.
Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA 1998;279:1903-1907.
Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-1285.
Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-l-converting enzyme protect against risk of cancer? Lancet 1998;352:179-184.
Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma in women? Am J Cardiol 1999;88:1090-1093.
TOMH Study, Neaton JD, Grimm RH, et al. Treatment of Mild Hypertension study (TOMH). Final results. JAMA 1993;270:713-724.
Grimm RH, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997;29:8-14.
TAIM Study, Wassertheil-Smoller S, Oberman A, et al. The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk and quality of life. Am J Hypertens 1992;5:37-44.
Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA 1998;279:1813-1816.
Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996;77:12B-16B.
Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-873.
Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-921.
Siscovick DS, Raghunathun TE, Psaty BM. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994;330:1852-1857.
Hoes AW, Grobbee DE, Lubsen J, et al. Diuretics, ß -blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995;123:481-487.
Messerli FH. Diuretic therapy and renal cell cardinoma-another controversy? (Editorial). Eur Heart J 1999;30:1441-1442.
Mason RP. Calcium channel blockers, apoptosis and cancer: Is there a biologic relationship. J Am Coll Cardiol 1999;34:1857-1866.